Wednesday, January 30, 2013 12:19:43 AM
This probably explains some of the margin compression lately. It was in the Q3 report and I ahdn't noticed it before-
"A major customer of Pharma-IR, which represents 10% of the Company’s total consolidated revenue for the nine months ended in July 31, 2012, placed Pharma-IR in a probation/review period which included the reduction of billing rates. Consequently, in order to maintain market share within Ireland, during the three months ended April 30, 2012, Pharma-IR reduced its billable margins to this customer and committed to an improvement on the level of service. Although management is actively pursuing new business development strategies geared to diversify our Ireland market customer base, at this point in time it is uncertain if these strategies will be able to produce the results necessary to offset the loss in the Ireland market margin."
All IMO only.
"A major customer of Pharma-IR, which represents 10% of the Company’s total consolidated revenue for the nine months ended in July 31, 2012, placed Pharma-IR in a probation/review period which included the reduction of billing rates. Consequently, in order to maintain market share within Ireland, during the three months ended April 30, 2012, Pharma-IR reduced its billable margins to this customer and committed to an improvement on the level of service. Although management is actively pursuing new business development strategies geared to diversify our Ireland market customer base, at this point in time it is uncertain if these strategies will be able to produce the results necessary to offset the loss in the Ireland market margin."
All IMO only.
I don't mind stealing bread from the mouths of decadence... But I can't feed on the powerless when my cup's already overfilled.
-Temple of the Dog
Recent PBSV News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 09:02:05 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/16/2026 08:20:11 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/16/2026 08:15:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 09:19:23 PM
- Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2026 • ACCESS Newswire • 03/17/2026 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/17/2026 09:00:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2026 10:07:11 PM
- Pharma-Bio Serv Announces Full Year Results and Special Dividend • ACCESS Newswire • 01/29/2026 10:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 01/29/2026 09:49:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/14/2026 01:49:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/14/2026 01:47:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/14/2026 01:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/15/2025 09:27:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/15/2025 08:53:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/16/2025 08:30:37 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/16/2025 08:26:21 PM
